サウスカロライナにおけるバーキットリンパ腫の臨床試験
サウスカロライナ内の拠点で、バーキットリンパ腫に関する5件の研究が参加者を募集しています。
サウスカロライナ内の都市
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Prisma Health Richland Hospital, Columbia
- Prisma Health Cancer Institute - Easley, Easley
- 他8件
被験者募集中第3相
18歳〜39歳 · 全性別 · 2026/10/02更新 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Medical University of South Carolina, Charleston
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。